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Abstract Tissue-type plasminogen activator (t-PA) is a positive
modulator of the plasminogen-plasmin system, which is involved
in bone remodeling. In the present study, 1,25-dihydroxyvitamin
D3 [1,25(OH)2D3] was found to stimulate t-PA gene expression
in ROS17/2.8 osteosarcoma cells. Transient transfection analy-
sis and in vitro DNA binding studies identified two vitamin
D-responsive elements (VDRE) in the human t-PA enhancer.
The first VDRE (bp 37175 to 37146) comprised an inverted
palindrome separated by 9 bp (IP9) overlapping a palindrome
separated by 3 bp. The second VDRE (bp 37315 to 37302) is an
IP2 element overlapping the previously identified retinoic acid-
responsive element. 1,25(OH)2D3 treatment of primary osteo-
blasts derived from t-PAlacZ transgenic mice containing 9 kb of
5P sequence of the human t-PA gene increased the number of
lacZ-positive cells, fitting with the probability model of enhancer
function.
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1. Introduction
The plasminogen^plasmin proteolytic cascade is involved in
di¡erent biological processes like ¢brinolysis [1], ovulation [2],
neuronal long-term potentiation [3], neuronal excitotoxin-in-
duced cell death [4] and bone remodeling [5]. The main com-
ponents of the system are urokinase- and tissue-type plas-
minogen activator (t-PA) which convert the inactive
plasminogen to the active serine protease plasmin. This pro-
teolytic cascade is controlled by plasminogen activator inhib-
itor 1 and K2-antiplasmin, which inhibit either t-PA or u-PA
and plasmin respectively [6].
t-PA is produced by osteoblasts and osteoclasts, cells in-
volved in the process of bone remodeling. Plasmin activity is
dispensable for bone resorption in explanted mouse fetal
metatarsal bones [7], suggesting that the t-PA-plasmin cascade
is rather involved in the activation of latent collagenase, reg-
ulating the processes of extracellular matrix degradation, and
activation of latent transforming growth factor L or latent
insulin-like growth factor leading to activation of osteoblasts
[5]. t-PA binding to an osteoclast or osteoblast cell membrane
receptor might also generate an intracellular signal triggering
cell motility, as was shown for urokinase-type plasminogen
activator binding to its receptor [8].
Expression of t-PA is subject to regulation by osteotrophic
hormones, like parathyroid hormone [9]. In addition, stimu-
lation of rat UMR106, human SAOS-2 osteosarcoma cells or
primary osteoblasts derived from rat calvariae with 1,25-dihy-
droxyvitamin D3 (1,25(OH)2D3) increased plasminogen acti-
vator activity, as was determined by the release of radiola-
beled ¢brin fragments in the presence of these cells or by
¢brin overlay gel experiments [10,11]. However, the role of
1,25(OH)2D3 in t-PA gene expression has not been investi-
gated in detail.
The e¡ects of 1,25(OH)2D3 on gene transcription are pri-
marily mediated by the vitamin D receptor (VDR), which
belongs to the superfamily of the steroid hormone receptors
[12]. Binding of 1,25(OH)2D3 to VDR induces formation of
homodimers or heterodimers with retinoid X receptors (RXR)
and subsequently binding to vitamin D-responsive elements
(VDRE) of target genes. The consensus binding site for such
a VDR/RXR heterodimer is a direct repeat of a hexanucleo-
tide sequence separated by 3 bp (DR3 ; GGGTCA gng
GGGGCA), although other types of binding elements, like
inverted palindromes, have also been reported [12]. The
DNA-bound VDR/RXR complex mediates transcriptional ac-
tivation by several mechanisms that, as for other nuclear re-
ceptors, are becoming unraveled: interactions with other tran-
scription factors and co-activators loosen the chromatin
structure and attract the RNA polymerase II pre-initiation
complex [13^16].
t-PA is produced not only in osteoblasts and osteoclasts,
but also in endothelial and neuronal cells where its expression
is regulated by several hormones. The upstream region of the
human t-PA gene contains an enhancer at 37.2 kb, which
mediates the response to retinoic acid (RA) and to all classical
steroid hormones, except estrogens [17,18]. These responses
are mediated through a perfect DR5 element (bp 37319;
t-PADR5) and a hormone-responsive unit comprising four
glucocorticoid-responsive elements (GRE ; bp 37501, bp
37703, bp 37942 and bp 37960), respectively. In contrast,
the t-PA proximal promoter, which is primarily regulated
through a cAMP-responsive element and two Sp1 binding
sites [19,20], contains no hormone-responsive elements.
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In this study we show that 1,25(OH)2D3 stimulates t-PA
gene expression in ROS 17/2.8 rat osteoblast cells and in pri-
mary osteoblasts from murine calvariae. The human t-PA
enhancer, located at 37.2 kb, is involved in the 1,25(OH)2D3
induction through two non-classical VDREs.
2. Materials and methods
2.1. Reagents
ROS 17/2.8 osteoblast cells were obtained from Dr. G. Rodan
(Merck Research Laboratories, West Point, PA, USA). The expres-
sion vector encoding the human retinoid X receptor K (pRSh-RXRK)
and the human vitamin D receptor (phVDR) were gifts from Dr. R.M.
Evans (The Salk Institute for Biological Studies, La Jolla, CA, USA)
and Dr. M. Haussler (University of Arizona, Tucson, AZ, USA), the
bacterially expressed and partially puri¢ed myc-hRXRK, myc-hVDR
and hRARL proteins from Dr. M. Baes (Laboratory for Clinical
Chemistry, University of Leuven, Leuven, Belgium), 1,25(OH)2D3
from Dr. J.P. van de Velde (Solvay, Weesp, The Netherlands). t-PA-
lacZ transgenic mice were obtained from Dr. W.D. Schleuning (Re-
search Laboratories, Schering AG Berlin, Germany). Trizol, Dulbec-
co’s modi¢ed Eagle’s F12 medium (MEM), KMEM and all medium
supplements were purchased from Life Technologies, Inc. (Ghent,
Belgium), tissue culture recipients from Corning, Inc. (New York,
NY, USA) and Becton Dickinson (Franklin Lakes, NJ, USA), chlor-
amphenicol from Sigma (St. Louis, MO, USA), DNA puri¢cation
columns from Qiagen (Chatsworth, CA, USA), acetyl-CoA and
[3H]acetyl-CoA from ICN Biomedicals (Costa Mesa, CA, USA), Lip-
oluma from Lumac-LSC (Olen, Belgium). Bradford reagent was pur-
chased from Bio-Rad (Hercules, CA, USA), 5-Br-4-Cl-3-indolyl-L-D-
galactopyranoside (X-gal) from Immunosource (Zoersel-Halle, Bel-
gium), Galacto Light system from Tropix, Inc. (Bedford, MA,
USA), poly(dIdC)Wpoly(dIdC) from Pharmacia (Roosendaal, The
Netherlands).
2.2. Cell culture
Rat osteoblast ROS 17/2.8 cells were maintained in supplemented
DMEM, containing L-alanyl-glutamine (1 mM), penicillin (100 IU/
ml), streptomycin (100 Wg/ml) and 10% heat-inactivated fetal calf se-
rum. For transfection, ROS 17/2.8 cells were seeded at a density of 2^
4U104 cells/cm2 and grown overnight at 37‡C in a humidi¢ed 95%
air, 5% CO2 atmosphere in medium with 2% charcoal-treated heat-
inactivated fetal calf serum. 1,25(OH)2D3 was dissolved in ethanol
and stored at 320‡C. The appropriate concentration was added to
the medium in a volume corresponding to 0.1% of the culture me-
dium. Control medium contained an equal amount of excipient.
2.3. Northern blot and t-PA-related antigen level determination
Total RNA was isolated from the cells using Trizol reagent and
puri¢ed according to the manufacturer’s instructions. For each con-
dition, 20 Wg of total RNA was separated by electrophoresis and
transferred as previously described [21]. Northern blots were probed
using standard hybridization techniques with a 0.8 kb mtPA cDNA
fragment [22] that had been 32P-random labeled, and reprobed with
an 18S RNA probe. Bands from autoradiographs were quanti¢ed on
the PhosphorImager (Molecular Dynamics) and the values for the
t-PA transcript were normalized to the corresponding values of the
18S RNA. Rat t-PA-related antigen levels were determined in the
conditioned medium by speci¢c enzyme-linked immunosorbent assays
(ELISA) as described [23].
2.4. Isolation, cell culture and analysis of primary murine osteoblasts
Transgenic mice contained the lacZ gene fused to either the com-
plete 9 kb of the upstream region of the human t-PA gene (bp 39578
to +197; lines 9kbht-PAlacZ #5706 and 9kbht-PAlacZ #6582) or to
3 kb of the latter region, with an internal deletion from 30.5 kb to
31.4 kb (line 2.1kbht-PAlacZ #7656) [24]. Genotyping was performed
using PCR [25]. t-PAlacZ transgenic males were mated with Swiss
wild type females. Primary osteoblasts were prepared by six sequential
digestions of individual calvariae from newborn mice in phosphate
bu¡er saline containing collagenase (2 mg/ml). Cells isolated from
the third digest on were pooled, plated out in four wells of a 12 well
plate and cultured in KMEM medium with 10% heat-inactivated fetal
calf serum at 37‡C in a humidi¢ed 95% air, 5% CO2 atmosphere. The
osteoblasts were grown to con£uence and were then treated with
either vehicle or 100 nM 1,25(OH)2D3. After 48 h the conditioned
medium was collected, cells were ¢xed with 2% formaldehyde and
0.2% glutaraldehyde for 10 min at 4‡C and stained with X-gal
(1 mg/ml) for 48 h at 30‡C or the L-galactosidase production was
quanti¢ed in a Berthold luminometer with the Galacto Light kit.
t-PA-related antigen levels were determined in the conditioned me-
dium by ELISA as described [26]. L-Galactosidase production and
t-PA-related antigen levels were corrected for protein concentration
of the cell lysate.
2.5. Reporter constructs
Isolation of t-PA upstream sequences and their incorporation in
chloramphenicol acetyltransferase (CAT) reporter plasmids have
been described previously [17]. All genomic sequences analyzed in
this study are numbered relative to the transcription start site [27].
t-PA9578-CAT and t-PA632-CAT contain the human t-PA sequence
from bp 39578 to +197 and from bp 3632 to +197 respectively.
t-PA2.4-632-CAT has in addition the t-PA enhancer (t-PA2.4 ; bp
39578 to 37144) in front of the t-PA promoter. t-PA2.4-TK-CAT
and t-PA1.9-TK-CAT have respectively the enhancer t-PA2.4 and the
3P deletion of the enhancer t-PA1.9 (bp 39578 to 37650) in front of
the TK promoter. Single mutations in the reporter constructs were
introduced with a PCR-based strategy, after which the double muta-
tion was cloned with standard techniques. All mutations were se-
quenced with the ABI 310 sequencer (Perkin Elmer). Sequences of
the oligonucleotides used in the mutagenesis are listed in Table 1.
2.6. Transfection analysis
For transient transfection of ROS 17/2.8 cells, the calcium phos-
phate co-precipitation method was applied to a six well dish using a
DNA mixture of 20^60 Wg of reporter plasmid with 1.4 Wg of the
indicated nuclear receptor expression plasmid. Cells were treated for
48 h with 10 nM 1,25(OH)2D3. Cell extracts were prepared by three
freeze-thaw cycles in 100 mM Tris-HCl pH 7.8, 5 mM EDTA. CAT
activity was determined by the liquid scintillation method [28]. All
data shown represent values obtained from at least two independent
experiments, each performed in triplicate (n = 6 or 9) and for which at
least two di¡erent plasmid preparations were used.
2.7. Electrophoretic mobility shift assay
The recombinant proteins myc-hVDR, hRAR and myc-hRXR were
overexpressed in BL21 Escherichia coli cells and partially puri¢ed by
ammonium sulfate precipitation as described previously [29]. Sequen-
ces of the oligonucleotides are listed in Table 1. 20 pmol DNA oligo-
nucleotides were labeled by T4 polynucleotide kinase in the presence
of [Q32P]ATP and puri¢ed via polyacrylamide gel electrophoresis. 20
ng of puri¢ed myc-hRXRK and myc-hVDR or hRARL were pre-in-
cubated for 15 min at room temperature before addition to the mix-
ture (10 mM Tris pH 8, 1 mM dithiothreitol, 500 WM EDTA, 80 mM
KCl, 0.1% Triton X-100, 1 Wg bovine serum albumin, 0.5 Wg poly-
(dIdC), 12% glycerol) containing 20 000 cpm of the labeled oligonu-
cleotide and incubated for 25 min at room temperature. Incubation
with the antibody directed against the myc tag was performed for
15 min between the pre-incubation and the ¢nal protein-DNA incu-
bation. The samples were loaded on a 4% polyacrylamide gel and
separated by electrophoresis at 4‡C for 90 min in 0.5UTris-borate
bu¡er. Gels were dried and the bands were visualized by autoradiog-
raphy at 380‡C for 12^48 h. Signals were quanti¢ed using the Phos-
phorImager (Molecular Dynamics).
3. Results
3.1. 1,25(OH)2D3 induces t-PA gene expression in ROS 17/2.8
osteoblast cells
Secretion of t-PA-related antigen by ROS 17/2.8 cells was
measured following treatment with 1,25(OH)2D3. A time-de-
pendent increase was observed for several doses with the high-
est induction of t-PA-related antigen secretion after 48 h (Fig.
1A). Regulation of t-PA gene expression by 1,25(OH)2D3 in
ROS 17/2.8 cells was also evaluated at the mRNA level. A
comparable time-dependent induction of message level was
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observed that preceded the alterations in antigen level by 24 h:
maximal increase was detected after 24 h (Fig. 1B).
3.2. 1,25(OH)2D3 induces LacZ expression in primary
osteoblasts isolated from t-PAlacZ transgenic mice
Primary osteoblasts were isolated from individual calvariae
of newborn mice from two transgenic lines containing the
lacZ gene fused to 9 kb (bp 39578 to +197) of the human
t-PA gene upstream region (respectively 9kbht-PAlacZ #5706
and 9kbht-PAlacZ #6582). Treatment of transgenic osteo-
blasts for 48 h with 100 nM 1,25(OH)2D3 increased the num-
ber of cells expressing the lacZ gene compared to untreated
cells as observed by light microscopy (2.2 þ 0.22- and
2.0 þ 0.25-fold increase for the 9kbht-PAlacZ #6582 and
#5706 cells respectively; Fig. 2A,B). Accordingly, L-galacto-
sidase activity in the treated cells was increased 1.9 þ 0.12-
and 1.7 þ 0.2-fold compared to untreated cells respectively
(Fig. 2C: P6 0.05). In contrast, osteoblasts derived from a
transgenic line containing the lacZ gene fused to 3 kb of
the upstream region of the human t-PA gene, with an inter-
nal deletion from 30.5 kb to 31.4 kb (2.1kbht-PAlacZ
#7656), did not express the lacZ gene either in the untreated
cells or in the 1,25(OH)2D3-stimulated cells (Fig. 2A). Wild
type cells did not show any detectable L-galactosidase expres-
sion.
Secreted murine t-PA-related antigen was also signi¢cantly
induced 2.0 þ 0.3-fold in the conditioned medium of treated
primary osteoblasts compared to untreated cells (8.9 ng/
ml þ 1.35 and 4.5 ng/ml þ 1.35 respectively; P6 0.01), indicat-
ing that 1,25(OH)2D3 acts in a similar way on the transgene
and on the endogenous t-PA gene (Fig. 2D).
In aggregate, these results indicate that the upstream region
of the human t-PA gene (bp 39578 to +197) mediated
1,25(OH)2D3 induction in primary mouse osteoblasts.
3.3. Delineation in the t-PA enhancer of the region mediating
the 1,25(OH)2D3 response
The human t-PA enhancer, located 7.2 kb upstream of the
transcription start site, mediates the response to RA and to all
classical steroid hormones except estrogens [17,18].
Table 1
Oligonucleotides
Name Sequence
VDRE 1 wt TCACAGTTCACTGCAACCTCAAATTTTCAGGTTCAAGG
VDRE 1 mut1 TAACAATTGACTGCAACCTCAAATTTTCAGGTTCAAGG
VDRE 1 mut4 TCACAGTTCACTGCAACCTCAAATTTTCATACATTGG
VDRE 1 mut6 TCACAATTGACTGCAACCTCAAATTTTCAGGTTCAAGG
VDRE 1 mut7 TCACAGTTCACTGATTTACCAAATTTTCAGGTTCAAGG
VDRE 1 mut8 TCACAATTGACTGATTTACCAAATTTTCAGGTTCAAGG
VDRE 1 mut9 TCACAGTTCACTGATTTACCAAATTTTCATACATTGG
t-PA DR5 GATCCACTCTGGGGTCACCCTGGGGTCAGAAGGAA
t-PA DR5 mod GATCCACTCTGCACTCACCCTGGGGTCAGAAGGAA
t-PA DR5 mut GATCCACTCTGGGTACCCCTGGGGATTGAAGGAA
oc VDRE ACTGTGCACTGGGTGAATGAGGACATGACTCA
t-PA NFI GAATAGGGCTTTGGCCGCTCTCCCAAAGGAGCCCG
Sequences of the oligonucleotides used in the competition analysis or to introduce site-speci¢c mutations in the t-PA2.0-TK-CAT vector. Puta-
tive VDRE half sites are double underlined in the wild type sequences. Introduced mutations are underlined.
Fig. 1. 1,25(OH)2D3 induction of t-PA-related antigen secretion and t-PA mRNA levels in ROS 17/2.8 cells. A: ROS 17/2.8 cells were treated
with indicated concentrations of 1,25(OH)2D3. Samples of the conditioned medium were taken after 24 h (F), 48 h ([NOCHAR:z.sqne]) and
72 h (E). Data are expressed as fold induction versus untreated cells (vehicle) and represent the mean þ S.E.M. (n = 3). B: Total RNA of ROS
17/2.8 cells treated with indicated concentrations of 1,25(OH)2D3 for 24 h or 48 h was subjected to a Northern blot analysis. RNA blots were
hybridized with a t-PA cDNA probe and rehybridized with an 18S rRNA probe. Quanti¢ed signals were normalized to the 18S rRNA signal
and are presented as fold induction compared to untreated cells. Given values represent the mean þ S.E.M. of three independent experiments
and a representative blot is shown.
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1,25(OH)2D3 responsiveness of reporter constructs containing
this enhancer was evaluated by transient transfection of ROS
17/2.8. Since it was observed that the endogenous VDR ex-
pression levels decreased in time, co-transfection of expression
vectors for RXR and VDR was performed.
Transient transfection of ROS 17/2.8 cells with t-PA9578-
CAT yielded only a moderate 1.4 þ 0.1-fold induction by 10
nM 1,25(OH)2D3. This is similar to the weak response to RA
or glucocorticoids that is observed after transient transfection
of HT1080 ¢brosarcoma cells with t-PA9578-CAT [17,18].
Since the responsive elements mediating the latter inductions
had been successfully identi¢ed using a reporter construct
containing the t-PA enhancer in front of the t-PA or TK
promoter, we followed the same approach for the delineation
of the VDREs. After treatment of the ROS 17/2.8 cells with
10 nM 1,25(OH)2D3 a 3.6 þ 0.2-fold induction compared to
the basal level was observed for a construct linking the t-PA
enhancer (t-PA2.4) to the t-PA promoter (t-PA2.4-632-CAT ;
Fig. 3). Since no response was found for the t-PA proximal
promoter alone (t-PA632-CAT), the enhancer was linked to a
heterologous promoter (t-PA2.4-TK-CAT) resulting in an
even stronger induction (5.8 þ 0.4-fold; Fig. 3).
Evaluation of a 3P deletion mutant of the t-PA enhancer
(t-PA1.9-TK-CAT) revealed an almost complete suppression
of the 1,25(OH)2D3 induction, indicating the presence of es-
sential responsive elements between bp 37650 and 37144
(t-PA0.5).
In conclusion, the enhancer located 7.2 kb upstream of the
Fig. 2. 1,25(OH)2D3 treatment of primary t-PAlacZ osteoblasts. Primary osteoblasts were isolated from newborn t-PAlacZ transgenic mice as
described in Section 2 and allowed to grow to con£uence before treatment for 48 h with 100 nM 1,25(OH)2D3. A: Cells were ¢xed and stained
with X-gal for 48 h. Representative pictures of untreated and 1,25(OH)2D3-treated cells derived from mice of the 9kbht-PAlacZ #5706, 9kbht-
PAlacZ #6582 and 2.1kbht-PAlacZ #7656 lines are shown. B: Number of stained cells was determined in a bright ¢eld microscopic analysis
with the aid of a gridded ocular. Fold induction of the number of stained cells treated with 1,25(OH)2D3 compared to control cells for the
9kbht-PAlacZ #5706 and 9kbht-PAlacZ #6582 lines is presented. C: Cells were harvested and L-galactosidase activity was measured and cor-
rected for protein concentration. Fold induction of L-galactosidase activity of 1,25(OH)2D3-treated cells versus control cells for the 9kbht-PA-
lacZ #5706 and 9kbht-PAlacZ #6582 lines is shown. D: ELISA for murine t-PA-related antigen was performed on the conditioned medium of
the primary osteoblasts and statistical signi¢cance (*) was at the P6 0.01 level (Student’s t-test).
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t-PA gene is able to mediate a response to 1,25(OH)2D3,
through cis-elements situated at its 3P end.
3.4. Interaction of VDR/RXR with sequences in t-PA0.5
Nucleotide sequence analysis of t-PA0.5 (bp 37650 and
37144) identi¢ed putative nuclear receptor binding sites. In-
terestingly, a half site identical to the mouse osteopontin
(mop) VDRE was present at bp 37153. This sequence consti-
tutes the 3P half site of a putative inverted palindromic ele-
ment separated by nine nucleotides (IP9), while the 5P half site
of this IP9 forms a palindromic element separated by three
nucleotides (Pal3) in combination with a more upstream half
site (Fig. 4A). Interaction of bacterially expressed myc-hVDR/
myc-hRXR heterodimers with an oligonucleotide comprising
this sequence (VDRE 1 : bp 37175 to 37146) was investigated
by electrophoretic mobility shift assay (EMSA; Fig. 4B).
Compared to oc VDRE, binding of myc-hVDR or myc-
hVDR/myc-hRXR to VDRE 1 resulted in a weak complex
Fig. 3. Delineation of a 1,25(OH)2D3-responsive region in the up-
stream sequences of the human t-PA gene. ROS 17/2.8 cells were
transiently co-transfected with expression vectors for VDR and
RXR and with CAT reporter constructs containing the TK or t-PA
promoter (TK-CAT ; t-PA632-CAT) alone or fused to the t-PA en-
hancer (t-PA2.4-632-CAT ; t-PA2.4-TK-CAT) or to a 3P deletion
mutant t-PA1.9 (t-PA1.9-TK-CAT). After treatment for 48 h with
10 nM 1,25(OH)2D3, cells were harvested and CAT activity was de-
termined. The results are the mean þ S.E.M. and are presented as
the fold induction of CAT activity of treated versus control cells.
Fig. 4. Identi¢cation of the sites mediating VDR/RXR binding to VDRE 1. A: Sequence of VDRE 1 (bp 37175 to 37146) and its putative
half sites (arrows). Mutated half sites are indicated with a bold cross. Putative binding elements are indicated at the top of the sequence. B:
EMSA was performed with the 32P-labeled oligonucleotide VDRE 1 or the control oc VDRE incubated with bacterially expressed myc-hRXR,
myc-hVDR or myc-hVDR/myc-hRXR proteins as described in Section 2. Because of di¡erences in binding a⁄nity the gel for VDRE 1 was ex-
posed longer. Myc-hVDR and myc-hVDR/myc-hRXR complexes are indicated with a black and white arrow respectively. The supershifted
complexes with antibody directed against the myc tag are indicated with a circle. C: EMSA was performed with 32P-labeled oc VDRE oligonu-
cleotide, myc-hVDR/myc-hRXR proteins and VDRE 1 competitor oligonucleotides as described in Section 2. Complexes formed with VDR ho-
modimers (lower complex) and VDR/RXR heterodimers were quanti¢ed and are shown below the graph. The relative intensities of the quanti-
¢ed signals are presented as percent binding compared to binding in the absence of competition. Competitor oligonucleotides are indicated
below the corresponding lanes and were added in 100-fold and 10-fold molar excess.
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(lanes i, k), which was supershifted and stabilized by addition
of an antibody directed against the myc tag (lanes j, l). The
role of the di¡erent half sites was evaluated in EMSA
competition experiments. Binding of myc-hVDR/myc-hRXR
to oc VDRE was challenged by competition with oligonucleo-
tides representing wild type (wt) or mutated sequences of
VDRE 1 (Fig. 4C). In contrast to the unrelated t-PANF-I
oligonucleotide, VDRE 1 wt was able to compete for VDR/
RXR binding to the oc VDRE (lanes 7, 8), although slightly
less e⁄ciently than oc VDRE itself (lanes 3, 4). Mutation of
either of the three half sites (VDRE 1 mut4, VDRE 1 mut6 and
VDRE 1 mut7) a¡ected competition e⁄ciency (lanes 9^14).
Combined mutation of the half sites constituting either the
Pal3 or the IP9 element further reduced binding of VDR/
RXR heterodimers to the VDRE 1 element (VDRE 1 mut8
and VDRE 1 mut9 ; lanes 15^18) suggesting that VDR/RXR
binding to VDRE 1 could be mediated through both ele-
ments.
Since a RA-responsive element (RARE) in the avian L3
integrin promoter also mediated a response to 1,25(OH)2D3
[30], we investigated the ability of VDR/RXR to interact with
the RARE t-PA DR5 in the t-PA enhancer (bp 37319 to
37303; VDRE 2) [17]. Indeed, myc-hVDR/myc-hRXR could
bind to an oligonucleotide comprising the t-PADR5 sequence
in EMSA (Fig. 5B). This DR5 element overlaps an inverted
palindromic element separated by 2 bp (IP2 ; Fig. 5A). Spe-
ci¢c mutation of the DR5 element, leaving the IP2 intact
(DR5 mod), disrupted RAR/RXR binding, but not myc-
hVDR/myc-hRXR binding. Upon mutation of the IP2 se-
quence (DR5 mut) the interaction with myc-hVDR/myc-
hRXR was also disrupted.
In conclusion, two VDREs have been identi¢ed in t-PA0.5 :
VDRE 1 consists of a Pal3 and an IP9 element, while VDRE 2
is an IP2 element which overlaps a functional RARE.
3.5. Functionality of the vitamin D-responsive elements
The VDRE 1 and VDRE 2 (t-PADR5) sites were mutated in
the t-PA2.0-TK-CAT reporter construct to the VDRE 1 mut1
and DR5 mut sequences (Table 1). These mutated reporter
constructs were evaluated for their 1,25(OH)2D3 responsive-
ness in ROS 17/2.8 cells co-transfected with expression vectors
for VDR and RXR as above. Mutation of VDRE 1 or VDRE
2 reduced 1,25(OH)2D3 induction as compared to wt t-PA2.0-
TK-CAT activity (Fig. 6, c or d versus b). Mutation of the two
sites simultaneously (Fig. 6, e) resulted in a further decrease of
1,25(OH)2D3 induction, although the response was not com-
pletely blunted.
Fig. 5. Binding of VDR/RXR and RAR/RXR heterodimers to VDRE 2. A: Sequence of VDRE 2 (bp 37338 to 37304) and its putative half
sites (arrows). Mutated half sites are indicated with a bold cross. Putative binding elements are indicated at the top of the sequence. B: EMSA
was performed as in Fig. 3B with the labeled oligonucleotides oc VDRE, t-PA DR5, t-PA DR5 mod and t-PA DR5 mut (sequences are pro-
vided in Table 1). Myc-hVDR, myc-hRXRK or hRARL proteins were added as indicated above the lanes.
Fig. 6. 1,25(OH)2D3 responsiveness of mutated t-PA VDREs in
the t-PA2.0-TK-CAT reporter construct in ROS 17/2.8 cells. A:
Schematic representation of the t-PA2.0-TK-CAT reporter con-
struct. Mutations are indicated with a bold bar. B: Transient
transfection of ROS 17/2.8 cells with TK-CAT (a), t-PA2.0-TK-CAT
(b), t-PA2.0VDRE1mut-TK-CAT (c), t-PA2.0DR5mut-TK-CAT (d),
t-PA2.0VDRE1/DR5mut-TK-CAT (e), and expression vectors for
RXR and VDR. Following stimulation with 10 nM 1,25(OH)2D3,
cells were harvested and CAT activity was determined. Results are
presented as described in the legend for Fig. 3.
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In summary, mutation of VDRE 1 and VDRE 2 reduces the
1,25(OH)2D3 induction of the t-PA-CAT reporter constructs
to the same level as t-PA1.9-TK-CAT, indicating that the
responsible VDREs in t-PA0.5 (bp 37650 and 37144) have
been identi¢ed. The minor residual induction could be caused
by additional cis-elements upstream of bp 37650 and by the
IP9 element in VDRE 1, which was not a¡ected by the VDRE
1 mutation.
4. Discussion
1,25(OH)2D3 was shown to induce the expression of the
endogenous t-PA gene in rat ROS 17/2.8 osteosarcoma cells
and of a lacZ gene linked to the 9 kb upstream sequence of
the human t-PA gene in primary osteoblasts derived from
t-PAlacZ transgenic mice. Two VDREs located in the t-PA
enhancer at 37.2 kb are involved in this response.
It was known that 1,25(OH)2D3 stimulates plasminogen
activator activity [10,11], but this was mainly attributed to a
decrease in PAI-1 activity [31]. We show that 1,25(OH)2D3
also upregulates t-PA gene expression at the mRNA and the
protein level in rat and murine osteoblasts. This induction
could be mimicked by the use of reporter constructs contain-
ing the upstream sequence of the human t-PA gene, implying
that 1,25(OH)2D3 regulation is conserved among species. A
sequence homologous to the t-PA enhancer is not known yet
in mouse and rat.
1,25(OH)2D3 induction was studied in three lines of trans-
genic mice containing 9 kb or 2.1 kb of the human t-PA gene
upstream sequence linked to the lacZ gene. Probably, because
of position e¡ect variegation, only a small part of the primary
osteoblast population derived from individual calvariae from
both 9kbht-PAlacZ lines expressed the lacZ gene. Both the
number of osteoblasts expressing the lacZ gene and the L-
galactosidase activity were increased 2-fold after 1,25(OH)2D3
treatment. This suggests that 1,25(OH)2D3 statistically in-
creases the chance that an osteoblast expresses the lacZ
gene (i.e. the t-PA gene), supporting the probability model
for enhancer function. In contrast to the classical model,
into which enhancers are thought to increase the rate of tran-
scription of a given gene in each cell, the probability model
favors an on/o¡ state of gene expression which is modulated
by enhancers [32]. It is assumed that enhancers do so via
disruption of the surrounding heterochromatin. The probabil-
ity model is based on observations with reporter constructs
containing enhancers in front of heterologous promoters that
were stably transfected into cells and assayed for resistance to
neomycin or for L-galactosidase expression [33,34]. Our ex-
periment is one of the ¢rst demonstrations that the on/o¡
state of a gene is modulated through an enhancer positioned
at its natural location, namely 7.2 kb upstream of its homol-
ogous promoter. Osteoblasts derived from the 2.1kbht-PA-
lacZ line do not express any L-galactosidase, suggesting that
the enhancer is necessary for the basal level of expression (the
on state) in these osteoblasts.
Since there is a RA- and steroid hormone-responsive en-
hancer located at 37.2 kb from the human t-PA gene, it
was investigated whether this enhancer was also involved in
1,25(OH)2D3 induction [17,18]. Transient transfection of ROS
17/2.8 cells with t-PA reporter constructs showed that the
enhancer linked to its natural or the heterologous TK pro-
moter was able to mediate a 1,25(OH)2D3 response. Evalua-
tion of a 3P deletion mutant revealed the involvement of the
region between bp 37650 and 37144 (t-PA0.5) in this induc-
tion. Two sequences (VDRE 1 and VDRE 2), located in this
region, were shown to interact with VDR in EMSA.
VDR/RXR binding has been observed to DR3 elements, as
in the mouse osteopontin gene [35], to IP9 elements as in the
human calbindin D9k gene [36], and to DR4 and DR6 type of
elements, as in the rat Pit1 and human phospholipase C-Q1
genes [37,38]. VDRE 1 (bp 37175 to 37146) belongs to the
family of complex VDREs which consists of multiple half
sites. Mutational analysis of the VDRE 1 sequence showed
that half sites at bp 37175, bp 37166 and bp 37151 are
involved in VDR/RXR binding. These three binding sites
are structured as a Pal3 element overlapping an IP9 element.
A similar structure comprising an IP9 and DR3 is present in
the rat osteocalcin promoter [36,39].
VDR/RXR heterodimers also interacted with an IP2 se-
quence (VDRE 2 ; bp 37315 to 37302) overlapping the
t-PA DR5 element, previously shown to mediate the RA in-
duction of the human t-PA gene [17]. Speci¢c mutagenesis
analysis demonstrated that the DR5 element interacted with
RAR/RXR heterodimers and that the IP2 element interacted
with VDR/RXR heterodimers. Responsive elements mediating
RA and 1,25(OH)2D3 induction have been described already
for the human osteocalcin promoter (DR6) [40], the human
25-hydroxyvitamin D3-24-hydroxylase promoter (two DR3
elements) [41] and the avian L3 integrin promoter (DR3+
DR9) [30]. In contrast to the responsive elements of the ¢rst
two promoters, the VDRE and the RARE can be discrimi-
nated in t-PA VDRE 2 and in the avian L3 integrin promoter:
RAR/RXR binds to a DR5 and a DR9 respectively, while
VDR/RXR binds to an IP2 and a DR3 respectively. Further
studies are required to investigate whether, just like for the
avian L3 integrin promoter, there is crosstalk between the
1,25(OH)2D3 and the RA pathways.
Despite the weak interaction with VDR/RXR in EMSA,
both VDRE 1 and VDRE 2 are directly involved in the
1,25(OH)2D3 response, since mutation of either of them in
t-PA2.0-TK-CAT strongly a¡ects the induction. However,
we cannot exclude that VDREs located outside t-PA0.5 (bp
37650 to 37144) are also involved in the 1,25(OH)2D3 in-
duction of the t-PA gene.
In conclusion, besides a RARE (t-PA DR5) and a steroid
hormone responsive unit, comprising four GREs, we have
identi¢ed two functional VDREs within the far upstream
t-PA enhancer, demonstrating the convergence of an addition-
al hormonal pathway on this unique regulatory element con-
veying modulation of t-PA gene expression.
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